Targeting Synaptic NMDA Receptor Co-agonism as a Therapy for Alzheimer's Disease?
Level V
Where this comes from
- Record sourced from PubMed, PMID 32130875.
- Also identified by DOI 10.1016/j.cmet.2020.02.009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Alzheimer's disease (AD) is associated with lower brain glucose metabolism. In this issue, Le Douce et al. (2020) show that this leads to insufficient astrocyte-dependent production of D-serine, co-agonist of synaptic NMDA receptors. Oral L-serine therapy rescues NMDA receptor hypofunction, plasticity, and cognition in an AD model, suggesting a new therapeutic strategy.
Medical subject headings
- Alzheimer Disease